For the Inventor, By the Inventor

Enter assignee name

Salisbury, United Kingdom

Gw Pharma Limited

USPTO Granted Patents = 66

% Expired Patents = 13.6

CIPO Patents = 12

EPO Patents = 39

Trademarks = 4

Forward Citations = 2,753

Loading Chart...

Loading Chart...

73 inventors (with patents filed for the assignee):

Geoffrey W Guy (32 out of 73 patents)

Brian Anthony Whittle (17 out of 28 patents)

Stephen Wright (17 out of 61 patents)

4. Alice Mead (10 out of 12 patents)

5. Colin Stott (9 out of 17 patents)

6. Orrin Devinsky (8 out of 28 patents)

7. Gary Stephens (8 out of 11 patents)

8. Claire Williams (8 out of 12 patents)

9. Rajiv Bobby Dave (7 out of 10 patents)

10. Tetsuro Kikuchi (6 out of 25 patents)

11. David Victor Downs (5 out of 5 patents)

12. Vincenzo Di Marzo (4 out of 13 patents)

13. Benjamin Whalley (4 out of 20 patents)

14. Thomas Hill (4 out of 4 patents)

15. Ben Whalley (4 out of 4 patents)

Core Competencies:

Phytocannabinoids

Cannabidiol

Cannabidivarin

Epilepsy Treatment

Pharmaceutical Formulation

Neuroprotective Agents

Cancer Treatment

Pain Management

Nausea Treatment

Inflammatory Diseases

Mental Disorders

Extraction Processes

66 patents: Sort by Forward Citations

1. 12121499 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2024-10-22),

2. 12023305 - Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy (2024-07-02),

3. 11413266 - Use of cannabinoids in the treatment of inflammatory skin diseases (2022-08-16),

4. 11318109 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2022-05-03),

5. 10807777 - Pharmaceutical formulation (2020-10-20),

6. 10799467 - Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy (2020-10-13),

7. 10758514 - Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour (2020-09-01),

8. 10729665 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2020-08-04),

9. 10653641 - Use of cannabinoids in the treatment of mental disorders (2020-05-19),

10. 10538373 - Pharmaceutical formulation (2020-01-21),

11. 10258580 - Cannabinoids for use in the treatment of neurodegenerative diseases or disorders (2019-04-16),

12. 10195159 - Processes and apparatus for extraction of active substances and enriched extracts from natural products (2019-02-05),

13. 10179683 - Pharmaceutical formulation (2019-01-15),

14. 10137095 - Use of cannabinoids in the treatment of epilepsy (2018-11-27),

15. 10111840 - Use of cannabinoids in the treatment of epilepsy (2018-10-30),

Company Overview

Gw Pharma Limited, based in Salisbury, UK, specializes in the development and manufacturing of cannabinoid-based therapies. The company focuses on harnessing the therapeutic potential of phytocannabinoids, particularly cannabidiol and cannabidivarin, to address various medical conditions. Their research encompasses areas such as epilepsy treatment, neuroprotection, cancer therapy, and pain management, aiming to provide innovative pharmaceutical formulations that enhance patient care and outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

66 Patents

#2 in Salisbury

#277 in United Kingdom

#11,155 in the World

Salisbury, United Kingdom

Gw Pharma Limited

Forward Citations = 2,753

73 inventors:

Geoffrey W Guy (32 out of 73 patents)

Brian Anthony Whittle (17 out of 28 patents)

Stephen Wright (17 out of 61 patents)

4. Alice Mead (10 out of 12 patents)

5. Colin Stott (9 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gw Pharma Limited. Retrieved from https://idiyas.com/company/gw-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…